



**David Tüller**

**Contact**

David Tüller

## Publications (9)

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Brinkert M, Muller O, Tüller D, Degrauwe S, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. *Cardiovasc Revasc Med* 2021; 34:3-10.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Rigamonti F, Lanz J, Tüller D, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. *J Am Heart Assoc* 2019; 8:e013607.

Iglesias J, Windecker S, Jüni P, Häner J, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Noble S, Tüller D, Roffi M, Heg D, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. *Circ Cardiovasc Interv* 2019; 12:e008024.

Pilgrim T, Jüni P, Eberli F, Hunziker L, Cuculi F, Kaiser C, Weilenmann D, Cook S, Siontis G, Moarof I, Muller O, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. *Lancet* 2018; 392:737-746.

Pilgrim T, Jüni P, Wenaweser P, Blöchliger S, Nietlispach F, Rigamonti F, Taniwaki M, Khattab A, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. *EuroIntervention* 2015; 11

Franzone A, Jüni P, Wenaweser P, Stortecky S, Räber L, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Pilgrim T, Windecker S. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. *Circ Cardiovasc Interv* 2015; 8

Pilgrim T, Jüni P, Wenaweser P, Eberli F, Noble S, Moschovitis A, Fahrni T, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Heg D, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. *Lancet* 2014; 384:2111-22.

Pilgrim T, Jüni P, Heg D, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Windecker S. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. *Am Heart J* 2014; 168:256-61.

Tüller C, Tüller D, Tamm M, Brutsche M. Hemodynamic effects of endobronchial application of ornipressin versus terlipressin. *Respiration; international review of thoracic diseases* 2004; 71:397-401.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)